Anavasi Diagnostics, a Washington-based startup, has received a total of $20.M in funding from the U.S. National Institutes of Health and individual investors to continue advancing its rapid test for COVID-19.
The company expects it will have the opportunity to file for emergency use authorization with the FDA in the near future for initial use with medical professionals. The Anavasi Diagnostics team predicts they will request additional approvals for their product to be used in a home setting in the coming months.